Clinical trial
A Safety and Efficacy Study of Xolair in Peanut Allergy
NCT00086606 · Genentech, Inc., Industry · Terminated
Key facts
| NCT number | NCT00086606 |
|---|---|
| Title | A Safety and Efficacy Study of Xolair in Peanut Allergy |
| Official title | A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Oral Food Challenge Trial of Xolair (Omalizumab) in Peanut Allergy |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Allergy |
| Intervention type | Drug |
| Interventions | Xolair (omalizumab) |
| Enrollment | 150 |
| Start date | Jun 1, 2004 |
| Completion | Apr 1, 2006 |
| First posted | Jul 9, 2004 |
| Last update posted | Jan 21, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: